GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Asset Turnover

Lisata Therapeutics (Lisata Therapeutics) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lisata Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Lisata Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $56.39 Mil. Therefore, Lisata Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Lisata Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -42.45%. It is also linked to ROA % through Du Pont Formula. Lisata Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -38.06%.


Lisata Therapeutics Asset Turnover Historical Data

The historical data trend for Lisata Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Asset Turnover Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lisata Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lisata Therapeutics's Asset Turnover

For the Biotechnology subindustry, Lisata Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Asset Turnover falls into.



Lisata Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lisata Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (73.034+54.694)/ 2 )
=0/63.864
=0.00

Lisata Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (58.089+54.694)/ 2 )
=0/56.3915
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lisata Therapeutics  (NAS:LSTA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lisata Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-21.46/50.553
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-21.46 / 0)*(0 / 56.3915)*(56.3915/ 50.553)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.1155
=ROA %*Equity Multiplier
=-38.06 %*1.1155
=-42.45 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lisata Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-21.46/56.3915
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-21.46 / 0)*(0 / 56.3915)
=Net Margin %*Asset Turnover
= %*0
=-38.06 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lisata Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics (Lisata Therapeutics) Business Description

Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Executives
David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427
Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583
Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117